Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Goldberg

Showing results (991-1000 of 1,004) with videos related to

Pageof 101
Sort By:
Leukemia & Lymphoma|September 3, 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplantJan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, et al.
Blood|September 14, 2019
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek, et al.
Cell|March 10, 2010
Distinct factors control histone variant H3.3 localization at specific genomic regionsAaron D Goldberg, Laura A Banaszynski, Kyung-Min Noh, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
Haematologica|April 2, 2026
Hypomethylating agents plus venetoclax <i>versus</i> intensive chemotherapy prior to transplant in high-risk acute myeloid leukemiaGuillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, et al.
Lancet (London, England)|June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
ACS Medicinal Chemistry Letters|November 19, 2025
A Novel Small Molecule Allosteric Inhibitor of IL-17A from a DNA-Encoded LibraryMarcos E Milla, Jonathan M Blevitt, Steven D Goldberg, et al.
American Journal of Hematology|October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemiaMaximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.
Journal of Viral Hepatitis|July 6, 2013
The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conferenceA Hatzakis, P Van Damme, K Alcorn, et al.
Pageof 101

Showing results (991-1000 of 1,004) with videos related to

Sort By:
Pageof 101
Leukemia & Lymphoma|September 3, 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplantJan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, et al.
Blood|September 14, 2019
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek, et al.
Cell|March 10, 2010
Distinct factors control histone variant H3.3 localization at specific genomic regionsAaron D Goldberg, Laura A Banaszynski, Kyung-Min Noh, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
Haematologica|April 2, 2026
Hypomethylating agents plus venetoclax <i>versus</i> intensive chemotherapy prior to transplant in high-risk acute myeloid leukemiaGuillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, et al.
Lancet (London, England)|June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
ACS Medicinal Chemistry Letters|November 19, 2025
A Novel Small Molecule Allosteric Inhibitor of IL-17A from a DNA-Encoded LibraryMarcos E Milla, Jonathan M Blevitt, Steven D Goldberg, et al.
American Journal of Hematology|October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemiaMaximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.
Journal of Viral Hepatitis|July 6, 2013
The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conferenceA Hatzakis, P Van Damme, K Alcorn, et al.
Pageof 101